Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
• Investors

• Our medicines

  

  • Arimidex
  • Crestor
  • Nexium
  • Seroquel
  • Symbicort
  • View all medicines

• Our responsibility

  

  • Animal research
  • Clinical trials
  • Patient safety
  • Sales and marketing
  • Pharmaceuticals in the environment
  • more information

• CEO interview

  • Video1
    David Brennan, our CEO discusses 2009 results and the outlook for the next five years.
    View part twoDownload podcast, vodcast and transcriptView financial results

• Latest news collapse

  • 11 December 2009 Advisory Committee Briefing Materials For Crestor sNDA Available On US FDA Web Site

    The U.S. Food and Drug Administration (FDA) today posted briefing materials in advance of 15 December 2009 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) to discuss the supplemental New Drug Application (sNDA) filed by AstraZeneca. The briefing materials can be found on the FDA web site.

  • 04 December 2009 US FDA Approves Seroquel XR For Add-On Treatment Of Major Depressive Disorder

    AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).  SEROQUEL XR is the only medication in its class approved by the FDA to treat both major depressive disorder as adjunctive therapy and acute depressive episodes associated with bipolar disorder as monotherapy.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next